U.S. market Closed. Opens in 2 hours 55 minutes

JANX | Janux Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 47.61 - 49.33
52 Week Range 7.79 - 65.60
Beta 3.52
Implied Volatility 106.37%
IV Rank 37.68%
Day's Volume 378,461
Average Volume 603,538
Shares Outstanding 52,482,000
Market Cap 2,569,518,720
Sector Healthcare
Industry Biotechnology
IPO Date 2021-06-11
Valuation
Profitability
Growth
Health
P/E Ratio -41.85
Forward P/E Ratio N/A
EPS -1.17
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 69
Country USA
Website JANX
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.
*Chart delayed
Analyzing fundamentals for JANX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is bad and Health is strong. For more detailed analysis please see JANX Fundamentals page.

Watching at JANX technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, but short-term trend is bearish. More technicals details can be found on JANX Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙